By Regeneron Pharmaceuticals announced on Monday that it will acquire the genetic testing business and most assets of 23andMe for $256 million in cash.
The transaction, which excludes 23andMe’s telehealth unit, is pending approval from a bankruptcy court, with the deal expected to close in the third quarter of 2025.
The acquisition follows 23andMe’s Chapter 11 bankruptcy filing in March, after a series of strategic missteps and mounting losses.
Once valued at nearly $6 billion at the height of the direct-to-consumer DNA testing boom, the company struggled to sustain growth beyond its initial product offering.
Access to genetic data
With this deal, Regeneron will gain access to a large database of consumer genetic information collected from more than 15 million customers.
The New York-based drugmaker said it intends to continue offering 23andMe’s testing services and will adopt the firm’s existing privacy standards.
“We assure 23andMe customers that we are committed to protecting the 23andMe dataset with our high standards of data privacy, security and ethical oversight and will advance its full potential to improve human health,” said Aris Baras, a senior vice president at Regeneron.
The company said it is prepared to work with a court-appointed privacy ombudsman to address concerns around data use and protection.
Privacy concerns remain
The nature of the data involved has raised questions among privacy experts.
“There probably haven’t been many instances in the past where supersensitive data was acquired by another company,” said Avi Collis, assistant professor at Carnegie Mellon University.
He noted the difficulty of maintaining anonymity and the variation in state privacy laws.
California’s attorney general issued a consumer alert following 23andMe’s bankruptcy, advising individuals to consider deleting their data.
The company previously stated that any buyer would be required to adhere to its privacy protocols.
23andMe’s transparency reports indicate that between 2015 and February this year, it received 11 requests from law enforcement for customer data and did not provide any without consent.
Strategic setback for 23andMe
The sale marks a turning point for 23andMe, which expanded beyond DNA kits into drug discovery and telehealth under co-founder Anne Wojcicki.
However, its efforts proved financially unsustainable, especially after the end of a key partnership with GlaxoSmithKline and the underperformance of its Lemonaid Health acquisition.
Regeneron, which operates its own genetics research center, said the acquisition supports its broader goals in medicine development.
The company reported a $4.4 billion profit last year and currently has six medicines in clinical trials backed by genetic research.
The post Regeneron acquires bankrupt 23andMe, pledges ethical use of genetic data appeared first on Invezz
